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Background: Quantifying latently infected cells is critical to evaluate the efﬁcacy of therapeutic strategies aimed at
reducing the size of the long-lived viral reservoir, but the low frequency of these cells makes this very challenging.
Methods:We developed TILDA (Tat/rev Induced Limiting Dilution Assay) to measure the frequency of cells with
inducible multiply-spliced HIV RNA, as these transcripts are usually absent in latently infected cells but induced
upon viral reactivation. TILDA requires less than a million cells, does not require RNA extraction and can be
completed in two days.
Findings: In suppressed individuals on ART, we found the median frequency of latently infected CD4+ T cells as
estimated by TILDA to be 24 cells/million, which was 48 times more than the frequency measured by the quanti-
tative viral outgrowth assay, and 6–27 times less than the frequencies of cells harbouring viral DNA measured by
PCR-based assays. TILDAmeasurements strongly correlated with most HIV DNA assays. The size of the latent res-
ervoir measured by TILDA was lower in subjects who initiated ART during the early compared to late stage of
infection (p = 0.011). In untreated HIV disease, the frequency of CD4+ cells carrying latent but inducible HIV
largely exceeded the frequency of actively producing cells, demonstrating that the majority of infected cells are
transcriptionally silent even in the absence of ART.
Interpretations:Our results suggest that TILDA is a reproducible and sensitive approach tomeasure the frequency of
productively and latently infected cells in clinical settings. We demonstrate that the latent reservoir represents a
substantial fraction of all infected cells prior to ART initiation.
Research in context: In thismanuscript, we describe the development of a novel assay thatmeasures themagnitude
of the latent HIV reservoir, themain barrier to HIV eradication. This novel assay, termed TILDA for Tat/rev Induced
Limiting Dilution Assay, requires only 10ml of blood, does not necessitate extraction of viral nucleic acids, is highly
reproducible, covers a wide dynamic range of reservoir sizes and can be completed in two days. As such, TILDA
may represent an alternative to existing assays used to evaluate the efﬁcacy of therapeutic strategies aimed at re-
ducing the size of the latent HIV reservoir.© 2015 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).erve University, Cleveland, OH
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Advances in the treatment of HIV infection have dramatically
reduced AIDS mortality and improved the quality of life of many people
living with HIV (Palella et al., 1998). The initiation of ART results in a
rapid drop in plasma viral load and in a substantial reduction in the
number of cells carrying proviral DNA in both blood and tissuesthe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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eradicate HIV. The virus persists in long-lived latently infected CD4+ T
cells that can produce infectious particles following T cell stimulation
(Finzi et al., 1997;Wong et al., 1997; Chun et al., 1997a). Themagnitude
of the latent reservoir is highly variable among virally suppressed indi-
viduals and is inﬂuenced by a variety of factors including the nadir
CD4+ T cell count (Boulassel et al., 2012), the CD4/CD8 ratio (Chun
et al., 2002), the time between infection and initiation of ART
(Josefsson et al., 2013; Strain et al., 2005; Archin et al., 2012; Buzon
et al., 2014; Ananworanich et al., 2012; Chomont et al., 2009) and, to a
lesser extent, the duration of therapy (Siliciano et al., 2003). Because
strategies targeting this latent reservoir are now being tested in clinical
trials, well-validated high-throughput assays that quantify this reservoir
are urgently needed to evaluate the effectiveness of these interventions.
Several assays have been developed to measure HIV persistence in
virally suppressed subjects who have received ART for years (Lewin
et al., 1999; Li et al., 2010; Siliciano and Siliciano, 2005; Yu et al., 2008;
Palmer et al., 2003; Vandergeeten et al., 2014; Pasternak et al., 2008;
Eriksson et al., 2013; Brussel and Sonigo, 2003; Rouzioux et al., 2005;
Strain et al., 2013; O'Doherty et al., 2002). The quantitative viral
outgrowth assay (Q-VOA) performed on puriﬁed resting CD4+ T cells
isolated from patients on suppressive ART is considered the gold stan-
dard method to measure the minimum frequency of latently infected
cells with replication competent virus (Finzi et al., 1997; Siliciano and
Siliciano, 2005; Chun et al., 1997b). However, this assay is time-
consuming, labour intensive, expensive and requires large volumes of
blood (120–180 ml). Recently, a more rapid and simpliﬁed version of
Q-VOA has been described (Laird et al., 2013), but this novel assay still
requires large number of cells and has not been adapted to a large
scale clinical trial. In addition, Ho et al. identiﬁed intact proviruses
from p24 negative wells of the virus outgrowth assay, which raises the
possibility that the Q-VOA underestimates the size of the in vivo latent
reservoir (Ho et al., 2013). This could be attributed to the fact that HIV
reactivation in this system is inherently stochastic, as recently proposed
(Weinberger and Weinberger, 2013).
An alternative to the Q-VOA is the use of PCR-based methods that
measure the frequency of cells harbouring HIV genomes (either total
or integrated HIV DNA) (Yu et al., 2008; Vandergeeten et al., 2014;
Brussel and Sonigo, 2003; Strain et al., 2013; O'Doherty et al., 2002).
Although these methods can be used in large cohort studies, they are
often criticized, as a large number of the viral genomes quantiﬁed by
these assays are not replication-competent. Indeed, total HIV DNA in
PBMCs and resting CD4+ T cells generally yields infected cell frequen-
cies that are 2–3 logs higher than the Q-VOA, reﬂecting the high occur-
rence of defective and non-inducible viral genomes (Eriksson et al.,
2013). Notwithstanding this limitation, measuring viral DNA, and
particularly integrated HIV DNA, has provided crucial information that
have contributed to the understanding of themechanisms of HIV persis-
tence during ART (Chomont et al., 2009; Agosto et al., 2011; Graf et al.,
2011; Mexas et al., 2012; Vandergeeten et al., 2013). Levels of HIV
DNA predict viral rebound after structured treatment interruption
(Williams et al., 2014; Yerly et al., 2004) and integrated HIV DNA is
the only assay that appears to correlate with Q-VOA (Eriksson et al.,
2013) although it is likely that frequencies of cells bearing HIV DNA
greatly overestimates the size of the inducible latent HIV reservoir
(Eriksson et al., 2013). These studies thus emphasize the need to devel-
op novel assays that would measure the size of the latent and inducible
HIV reservoir in a simple, reproducible and cost-effective manner.
An ideal assay would measure the frequency of latently infected
CD4+ T cells without relying on the ampliﬁcation of viral replication,
which is difﬁcult to control and requires at least a week of cell culture.
Measuring the production of viral particles in culture supernatants of
stimulated cells is attractive (Cillo et al., 2014), but would require ultra-
centrifugation and RNA extraction steps that are not desirable for a
clinical trial scalable assay. Cell associated RNA is an alternative virolog-
ical marker that can be easily measured in a limiting dilution assay.Low amounts of cell-associated unsplicedHIV RNA are frequently de-
tected in PBMCs from virally suppressed subjects on ART (Lewin et al.,
1999; Furtado et al., 1999; Fischer et al., 2002; Schmid et al., 2010;
Pasternak et al., 2009), as well as in latently infected CD4+ T cells that
do not produce HIV particles (Fischer et al., 2004; Peng et al., 1995;
Hermankova et al., 2003), and therefore, cannot be used as a surrogate
for viral release (Cillo et al., 2014; Kearney, 2015). In contrast, tat/rev
multiply spliced RNA (msRNA) reﬂects the ability of a cell to produce
virus (Lewin et al., 1999; Pasternak et al., 2008, 2009; Fischer et al.,
2002, 2004; Schmid et al., 2010; Peng et al., 1995; Hermankova et al.,
2003; Vesanen et al., 1997; Sonza et al., 2002). Of note, recent data
indicate that tat positive feedback alone may be sufﬁcient in reversing
latency, independent of cellular activation (Razooky et al., 2015),
suggesting that tat transcripts may be used as a surrogate for productive
infection. This is consistent with the fact that direct addition of tat acti-
vates viral expression in resting CD4+ T cells without requiring cellular
activation (Lassen et al., 2006; Lin et al., 2003). In addition, many defec-
tive HIV genomes have deletions that encompass the tat and rev genes
(Ho et al., 2013), indicating that transcripts from these genes are very
unlikely to be generated in cells harbouring defective proviruses. This
provides a rationale for the development of a sensitive assay that can
detect tat/revmsRNA upon maximal stimulation.
Here, we report the development of TILDA, a novel assay that mea-
sures the frequency of cells harbouring viral genomes that produce
tat/rev multiply-spliced HIV RNA upon maximal stimulation. By com-
bining ultrasensitive detection of msRNA and maximal activation of
CD4+ T cells in a limiting dilution format, this method allowed us to
measure the frequency of cells capable of being induced to produce
HIV RNA transcripts. Signiﬁcantly, this assay has potential for applica-
tion in larger clinical trials and cohort studies as it requires only 10 ml
of blood, is robust, sensitive, covers a wide dynamic range of reservoir
size and can be completed in two days.2. Methods
2.1. Participants and Samples
Samples from 20 subjects on stably suppressive ART and from 13 vi-
remic subjects not receiving ART at the time of sampling were used in
this study. None of the participants under ART experienced any detect-
able plasma viremia at the time of study, as assessed by viral load mea-
surement using the Ampliprep/Cobas Taqman HIV-1 Test v 2.0 (Roche),
with a detection limit of 20 copies/ml of plasma. These subjects had an
undetectable viral load for an average of 6 years (range 3–17 years). All
participants underwent leukapheresis to collect large numbers of
PBMCs. Subjects characteristics are summarized in Table 1.
Data presented in Figs. 2 and 3were generated by analysing samples
obtained from individualswhoparticipated in a previous study aimed at
comparing different assays to measure HIV persistence (Eriksson et al.,
2013). Brieﬂy, this study enrolled 30 subjects from two well-
established cohorts at the University of California San Francisco
(UCSF). Samples from 27 of these participantswere used for the present
study (17 from the SCOPE cohort and 10 from the OPTIONS cohort). All
of the 27 subjects had at least 36 months of continuous ART at study
entry with no regimen changes in the preceding 24 weeks and mainte-
nance of plasma HIV RNA levels below the limit of detection of conven-
tional assays for at least 36 months (intermittent isolated episodes of
detectable low-level viremia were allowed). Primary or recent HIV
infection was deﬁned if one or several of these 3 criteria were met:
(Palella et al., 1998) repeated plasma HIV RNA N5000 copies/ml com-
bined with a negative or indeterminate HIV antibody test; (Murray
et al., 2014) seroconversion within 6 months of a documented negative
HIV antibody test; (Garrigue et al., 2000) a history compatible with pri-
mary HIV infection (including no prior positive HIV antibody tests) and
laboratory testing consistent with recent infection on the “detuned”
Table 1
Participant characteristics.
Sexa CD4 count (cells/μl) CD8 count (cells/μl) HIV viral load (copies/ml) Duration of HIV infection (years)b Duration of ART (years)c ART regimend
Virally suppressed subjects
ART1 NA 1177 935 b20 NA 6.5 NA
ART2 M 1183 912 b20 25.6 3.4 ABC/3TC/ATV
ART3 M 1112 594 b20 12.9 12.9 ABC/3TC/NVP
ART4 M 326 1085 b20 6.2 6.1 TDF/FTC/EFV
ART5 M 612 834 b20 25.7 16.9 NA
ART6 M 1065 1408 b20 15.0 8.2 TDF/FTC/EFV
ART7 M 1145 1410 b20 6.1 5.8 TDF/FTC/LPV/r
ART8 M 1095 736 b20 22.1 6.2 TDF/FTC/EFV
ART9 M 876 1389 b20 5.7 5.0 ABC/3TC/EFV
ART10 F 522 238 b20 22.1 7.5 TDF/FTC/ATV/r
ART11 F 460 1879 b20 5.4 4.4 TDF/FTC/RAL/LPV/r
ART12 F 355 815 b20 21.1 4.7 TDF/FTC/DRV/r
ART13 M 289 512 b20 16.2 3.0 TDF/FTC/LPV/r
ART14 F 351 344 b20 15.1 3.6 TDF/FTC/ATV/r
ART15 M 734 703 b20 7.2 2.5 TDF/FTC/RAL
ART16 M 267 518 b20 NA 3.8 TDF/FTC/EFV
ART17 M 1102 875 b20 NA NA TDF/FTC/ATV
ART18 M 291 491 b20 10.4 2.9 ABC/3TC/ATV/r
ART19 M 1897 830 b20 NA 6.1 TDF/FTC/EFV
ART20 M 387 625 b20 NA 6.3 ABC/3TC/ATV
Median
[IQR]
734 [353–1107] 815 [556–1010] b20 [b20– b 20] 15 [6.7–21.6] 5.8 [3.7–6.4]
Viremic subjects
VIR1 F 319 470 51,000 11.8 – –
VIR2 M 434 2497 51,000 2.5 – –
VIR3 F 548 751 23,000 18.0 – –
VIR4 M 480 1552 3300 5.7 – –
VIR5 M 258 1704 400,000 5.1 – –
VIR6 M 185 647 50,000 9.0 – –
VIR7 F 284 605 21,000 5.1 – –
VIR8 F 681 543 15,000 8.0 – –
VIR9 M 499 1590 52,915 9.9 – –
VIR10 NA 543 896 6077 4.0 – –
VIR11 M 732 1506 51,647 0.4 – –
VIR12 M 506 948 2959 1.1 – –
VIR13 M 1400 2040 8082 0.4 – –
Median
[IQR]
499 [319–548] 948 [647–1590] 23,000 [8082–51,000] 5.1 [2.5–9.0]
a NA: not available.
b Duration of HIV infection was calculated from the date of diagnosis of HIV infection.
c Time of documented suppression of viremia to b50 copies/ml on ART.
d Drugabbreviation: 3TC, lamivudine; ABC, abacavir; ATV, atazanavir; ATV/r, atazanavir boostedwith ritonavir; DRV/r, darunavir boostedwith ritonavir; EFV, efavirenz; FTC, emtricitabine;
LPV/r, lopinavir boosted with ritonavir; NVP, nevirapine; RAL, raltegravir; TDF, tenofovir disoproxil fumarate.
876 F.A. Procopio et al. / EBioMedicine 2 (2015) 874–883antibody EIA. Characteristics of these participants can be found in
Eriksson et al. (2013).
This study was approved by the Martin Health System Institutional
review board and by the UCSF Committee on Human Research. All
study subjects provided written informed consent prior to participation
in the study.
2.2. Isolation of CD4 T cells
PBMCs were isolated from the leukapheresis product by Ficoll
Hypaque density gradient centrifugation and cryopreserved in liquid
nitrogen. Upon thawing of the PBMCs, total CD4+ T cells were isolated
by negative magnetic selection (Stemcell technologies). The purity of
enriched CD4+ T cells was generally greater than 95%, as assessed by
ﬂow cytometry.
2.3. TILDA
Enriched CD4+ T cells were resuspended at 2 × 106 cells/ml in
RPMI + 10% foetal bovine serum and rested for 3–5 h at 37 °C, 5%
CO2. In some experiments, antiretroviral drugs were added to the
culture medium (200 nM raltegravir, 100 nM efavirenz and 180 nM
AZT). CD4+ T cells were stimulated for 12 h with 100 ng/ml PMA and
1 μg/ml ionomycin (both from Sigma). The duration of 12 h was basedon kinetic experiments demonstrating maximal production of tat/rev
RNA and preserved cell viability at this time point (not shown).
After stimulation, cells were washed in RPMI, counted and serially
diluted to 18 × 106 cells/ml, 9 × 106 cells/ml, 3 × 106 cells/ml and
1 × 106 cells/ml in culture medium. 1 μl of the cell suspension from
each serial dilution was distributed in 22 to 24 wells of a 96 well plate
containing 5 μl of 2× reaction buffer from the SuperScript III Platinum
One-Step qRT-PCR Kit (Life Technologies) corresponding to 18,000,
9000, 3000 and 1000 cells per well. Different cell numbers were used
for samples obtained from viremic, untreated HIV-infected individuals
(9000; 3000; 1000 and 333 cells per well). In some experiments, a
fraction of the isolated CD4+ T cells were immediately distributed in
limiting dilutions after thawing to quantify the frequency of cells that
spontaneously produce HIV msRNA (no stimulation). Similar frequen-
cies of positive cells were measured by TILDA whether the cells were
distributed immediately after thawing or after 12 h of resting (not
shown). Pre-ampliﬁcation was carried out by adding 5 μl of a PCR mix
containing 0.2 μl Superscript III Platinum Taq (Life Technologies),
0.1 μl RNase inhibitor (Life Technologies), 0.125 μl of each primer
(tat1.4 and rev both at 20 μM), 2.2 μl Tris–EDTA (TE) buffer and
2.25 μl H2O to each well (ﬁnal reaction volume= 11 μl). The sequences
of the oligonucleotides were slightly adapted from Pasternak et al.
(2008): tat1.4: 5′-TGG CAG GAA GAA GCG GAG A-3′; rev: 5′-GGA TCT
GTC TCT GTC TCT CTC TCC ACC-3′. Pre-ampliﬁcation was carried out
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naturation at 95 °C for 2min, 24 cycles of ampliﬁcation (95 °C 15 s, 60 °C
4 min) on a C1000 PCR instrument (Biorad). At the end of the pre-
ampliﬁcation, 40 μl of TE buffer was added to each well and 1 μl of the
diluted PCR products was used as template for the tat/rev real-time
PCR reaction. This reaction was performed by adding 5 μl of the
Lightcycler Probe Master buffer (Roche Applied Sciences), 0.2 μl of
each primer (tat2 and rev, both at 20 μM), 0.2 μl of the probe HIV
FamZen at 5 μM and 3.4 μl H2O to each well (ﬁnal reaction volume =
10 μl). Sequence of tat2 and the HIV probe were also adapted from
(Pasternak et al., 2008): tat2: 5′- ACA GTC AGA CTC ATC AAG TTT CTC
TAT CAA AGC A -3′. Probe HIV: 5′-/56-FAM/TTC CTT CGG /ZEN/GCC
TGT CGGGTC CC/3IABkFQ/-3′. All primers and probes were synthesized
by IDT. The real-time PCR reaction was carried out in a Light Cycler 480
II (Roche Life Science) using the following programme: Preincubation
95 °C for 10min, 45 cycles of 95 °C 10 s, 60 °C 30 s, 72 °C 1 s and a cooling
step at 40 °C fro 30 s. Positive wells at each dilution were counted and
the maximum likelihood method was used to calculate the frequency
of cells with inducible HIV msRNA (http://bioinf.wehi.edu.au/
software/elda).
2.4. Statistical Analysis
Baseline and induced TILDA values were compared using the
Wilcoxon matched-pairs signed rank test. For correlations between
values obtained with different assays, normality of the log transformed
virologic data was tested with the D'Agostino–Pearson test. With the
exception of total HIV DNA in resting CD4+ T cells and residual viremia
by single copy assay, all virologic datamet the normality test and corre-
lations were performed on log-transformed values using the Pearson
test. When the data did not meet the normality test, the Spearman
test was used. When the result of an assay was negative (below the
limit of detection), an imputed value representing the lower of the
limit of detection was used in the calculation of the Pearson correlation
coefﬁcient. In the case of the single-copy assay for HIV-1 RNA in plasma,
for which one-third of the measurements was below the limit of detec-
tion (0.2 copies/ml), a low imputed value of 0.1 was used to calculate
the Spearman rank correlation coefﬁcient. Virologic data obtained
from subjects who started ART during the early and chronic phases of
infection were compared using a two-tailed Mann–Whitney test. Data
analysis was done using Microsoft Excel and Prism 6.0.
3. Results
3.1. Principle of TILDA
We sought to develop an assay that detects tat/revmsRNA (adapted
from Pasternak et al., 2008) in maximally activated CD4+ T cells, using
a limiting dilution format, postulating that this method will allow us to
measure the frequency of cells harbouring inducible viruses. We chose
to activate the cells with phorbol 12-myristate 13-acetate (PMA),
whichhas been shown to induce a rapid onset of increased transcription
from the HIV LTR in latently infected cell lines (Li et al., 1991), induces
higher levels of viral production than PHA (Tong-Starkesen et al.,
1989) and activates rare T cell subsets (Wang et al., 2013). Ionomycin,
a calcium ionophore, is added to trigger calcium release, a requirement
for N-FAT signalling. PMA ionomycin has been shown to induce high
levels of viral production in several primary cell models of HIV latency
(Spina et al., 2013) as well as in CD4+ T cells from virally suppressed
individuals (Bullen et al., 2014; Laird et al., 2014). After stimulation,
cells are distributed in 24 replicate wells in a 96 well plate and a nested
PCR amplifying tat/rev transcripts is directly performed without RNA
extraction (Fig. 1A). Using the maximum likelihood method, the fre-
quency of cells producing msRNA is calculated. TILDA can also be used
to measure the frequency of CD4+ T cells that spontaneously produce
msRNA ex vivo by omitting the stimulation step.3.2. TILDA is Speciﬁc, Sensitive and Reproducible
We ﬁrst evaluated the sensitivity and speciﬁcity of TILDA.We infect-
ed activated CD4+ T cells with an infectious HIV clone containing a GFP
reporter (NL4-3 nef IRES GFP). Two days postinfection,we sorted GFP+
and GFP- cells and used our assay to detect tat/revmsRNA in wells con-
taining single cells (Fig. S1A). Among 48well containing GFP+ cells, 42
were positive for HIV DNAandGAPDH (88%). 79% (33/42) of thesewere
positive by TILDA. In contrast, none of the 48 wells containing GFP neg-
ative cells were positive for msRNA, in spite of a signiﬁcant fraction of
these well containing HIV DNA (42/48, 88%). These results suggested
that the presence of msRNA is a speciﬁc surrogate for the production
of viral proteins, at least in this in vitro system of HIV infection.
Using samples obtained from 4 virally suppressed subjects, we deter-
mined the robustness of TILDA i.e., intra- and inter-assay coefﬁcients of
variation; we measured the frequency of CD4+ T cells producing tat/
rev msRNA upon stimulation with PMA/ionomycin in duplicate plates
or in up to 4 independent experiments performed by different operators.
The intra and inter-assay coefﬁcients of variation of TILDAwere 0.15 and
0.21, respectively (Fig. S1B) conﬁrming the robustness of this assay. The
theoretical dynamic range of TILDA is N3logs10 with minimal and maxi-
mal detectable values of 1.4 and 3185 cells/106 CD4+T cells, respective-
ly. Of note, all the experimental values determined in this study ranged
over 3 logs, a dynamic range of TILDA that is large enough to efﬁciently
measure low frequency of infected cells as is the case in the vastmajority
of virally suppressed individuals (Fig. S1C). Importantly, the limit of de-
tection of TILDA indicated above (1.4 cells/106 CD4+ T cells) is based
on the number of cells plated in a typical experiment (744,000 cells cor-
responding to 24 × 18,000+ 24 × 9000+ 24 × 3000+ 24 × 1000) and
can further be lowered by increasing the number of cells assayed inmul-
tiple plates.
3.3. TILDA Measures the Frequency of CD4+ T cells With Inducible msRNA
in Virally Suppressed Individuals on ART
Weused TILDA tomeasure the frequency of CD4+ T cells producing
tat/rev msRNA in samples from 20 virally suppressed subjects on
suppressive ART for a median time of 6 years (Table 1). As expected,
the frequency of cells spontaneously producing msRNA was low
(median = 2.7 cells/106 CD4+ T cells, Fig. 1B), and even below the
limit of detection in 5 out of 19 samples (26%). CD4+ T cells producing
tat/rev RNA were detected in all samples upon stimulation, with a me-
dian frequency of cells producing msRNA of 50 cells/106 CD4+ T cells
(p b 0.0001). By subtracting the baseline from the induced values, we
calculated the frequency of cells carrying inducible HIV. We estimated
that only 7.3% of CD4+ T cells with the ability to generate msRNA pro-
duced these transcripts spontaneously, whereas themajority (92.7%) of
cells were devoid of msRNA ex vivo but produced them upon stimula-
tion with PMA/Ionmycin (Fig. 1C). These results are in line with previ-
ous reports demonstrating that the majority of infected cells in
individuals on suppressive ART, harbour latent HIV and do not sponta-
neously produce viral particles (Chun et al., 1997b; Finzi et al., 1999;
Chun et al., 2003). These results demonstrated that TILDA can be used
to measure the frequency of CD4+ T cells that have the ability to pro-
duce HIV msRNA upon stimulation in virally suppressed subjects.
3.4. TILDA Values Correlate With Several Assays Measuring HIV Persistence
During ART
We next compared the frequency of latently infected CD4+ T cells
measured by TILDA with values obtained from a variety of well-
established assays (Siliciano and Siliciano, 2005; Yu et al., 2008; Palmer
et al., 2003; Strain et al., 2013; Yukl et al., 2010). For this purpose, we
used samples that were originally used to compare Q-VOA with several
PCR-based assays (Table 2) (Eriksson et al., 2013). In these samples ob-
tained from 27 participants of the SCOPE and Options studies, we found
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Fig. 1. TILDA can be used to measure the frequency of persistently infected cells in blood samples from virally suppressed subjects. (A) Principle of TILDA: PBMCs were isolated from 10–
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subjects. Horizontal bars indicatemedian values. For samples inwhich nopositive cellswere detected at baseline, the limit of detection (based on cell input) is plotted and represented as a
crossed circle. P value was obtained from theWilcoxon matched-pairs signed rank test. (C) Proportion of CD4+ T cells that produce msRNA spontaneously or after stimulation in virally
suppressed subjects on ART. Only samples with detectable values at baseline (panel B) are represented.
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TILDAwas 24 cells/106 CD4+T cells (range 1.4–101 cells/million), which
was 48 times higher than frequencies measured by Q-VOA (median =
0.5, range 0.03–16 cells/106 CD4+ T cells), and 6–27 times lower than
frequencies of infected cells measured by PCR-based assays (Table 2).
We then determined correlations between the values obtained by
TILDA and the other assays used tomeasure the size of theHIV reservoir
using samples from the same group of subjects. TILDA values wereTable 2
Results from the virological assays used in this study.
Q-VOA TILDA Tot. HIV DNA
in PBMCs
Methoda Cell culture in limiting
dilution
Stimulation and PCR in
limiting dilution
ddPCR
Sample Resting CD4+ T cells Total CD4+ T cells PBMCs
Unit Infectious unit/106
cells
Cells expressing
msRNA/106 cells
Copies/106 cells
n samples 27 27 27
Median 0.5 23.8 150
Ratio with TILDAb 0.021 – 6.3
Max. value 16 100.6 1858
Min. value 0.0315 1.4 1
a ddPCR: droplet digital PCR; SCA: single copy assay. NA: not applicable.
b Median values were used to calculate the ratio. Samples for which one of the 2 measurem
c Ratio between GALT DNA and TILDA measured in blood.positively correlated with the frequency of PBMCs harbouring total
HIV DNA (r = 0.38, p = 0.05, Fig. 2A) and integrated HIV DNA (r =
0.68, p = 0.002, Fig. 2B) as well as with the frequency of rectal CD4+
T cells harbouring total HIVDNA (r=0.70, p=0.002, Fig. 2C). Although
TILDA values tended to correlate with the frequencies of resting CD4+
T cells harbouring total and integrated HIV DNA, these correlations did
not reach statistical signiﬁcance (ρ = 0.48, p = 0.083 and r = 0.47,
p = 0.076, respectively, Fig. 2D and E). Of note, the number of samplesTot. HIV DNA
in CD4
Int. HIV DNA
in PBMCs
Int. HIV DNA
in CD4
Tot. HIV DNA
in GALT cells
Residual
viremia
plasma
ddPCR alu-PCR alu-PCR ddPCR SCA
Resting CD4+
T cells
PBMCs Resting CD4+
T cells
GALT CD4+
T cells
Plasma
Copies/106 cells Copies/106 cells Copies/106 cells Copies/106 cells Copies/ml
14 18 15 17 27
307.5 234.5 767 5301 0.5
13.4 9.0 27.1 226c NA
1200 1248 2997 13,388 2.2
1 19 108 259 0.1
ents used in each comparison was not performed were excluded.
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Fig. 2. TILDA correlates with several measures of HIV persistence. (A) Correlation between TILDA and the droplet digital PCR assay for HIV DNA in PBMCs. (B) Correlation between TILDA
and the Alu-PCR assay for HIV DNA in PBMCs. (C) Correlation between TILDA and the droplet digital PCR assay for HIV DNA in rectal CD4+ T cells. (D) Correlation between TILDA and the
droplet digital PCR assay for HIVDNA in restingCD4+T cells. (E) Correlation between TILDAand theAlu-PCR assay forHIVDNA in resting CD4+T cells. (F) Correlation betweenTILDAand
single copy assay for residual viremia. (G) Correlation between TILDA andQ-VOA in resting CD4+T cells. Black circles and grey circles denote subjectswho startedART during chronic and
early infection, respectively. P values were obtained from the Pearson (A, B, C, E, G) or Spearman test (D, F), according to the results of the normality test (see Methods).
879F.A. Procopio et al. / EBioMedicine 2 (2015) 874–883in which total and integrated HIV DNAweremeasured in resting CD4+
T cells was limited (n = 14 and 15, respectively, Table 2), which
curtailed our capacity to detect signiﬁcant associations between TILDA
and these two assays. TILDA values did not correlate signiﬁcantly with
residual viremia, although a trend for a negative association was noted
(ρ = −0.35, p = 0.070, Fig. 2F). The frequency of resting CD4+
T cells harbouring replication competent HIV measured by Q-VOA
tended to correlate with TILDA, but this was not statistically signiﬁcant
in this relatively small population of virally suppressed individuals (r=
0.33, p = 0.095, Fig. 2G); this may be attributed to the fact that Q-VOA
uses resting CD4+ T cells, whereas TILDA is performed on total CD4+
T cells that include homeostatically proliferating cells. Altogether,
these results demonstrate that TILDA can be efﬁciently used tomeasure
the frequency of CD4+ T cells producing msRNA upon stimulation, afrequency that correlates with several assays that measure HIV
persistence.
3.5. Initiation of ART During Early HIV Infection Leads to a Restricted Size of
the Reservoir During Therapy Measured by TILDA
Wemeasured the frequency of infected cells with inducible msRNA
in virally suppressed subjects who initiated ART during recent (n= 10)
or chronic (n=17) infection (Fig. 3). Using TILDA,we observed that the
size of the reservoir was signiﬁcantly smaller in subjects who started
ART during recent infection (b6 months) when compared to those
who initiated therapy at a later stage of the disease (median frequencies
of 11 and 29 cells/106 CD4+ T cells in early and chronic infection re-
spectively, p = 0.011). This was in line with the results form previous
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Fig. 3. Initiation of ART during early HIV infection leads to a restricted size of the reservoir
measured by TILDA. The frequency of cells harbouring inducible msRNAwasmeasured by
TILDA on CD4+ T cells obtained from subjects who started ART during chronic (n = 17,
red circles) or recent (n = 10, blue circles) infection. Horizontal bars indicate median
values. P value was obtained from the Mann–Whitney test.
880 F.A. Procopio et al. / EBioMedicine 2 (2015) 874–883studies (Strain et al., 2005; Archin et al., 2012; Buzon et al., 2014;
Ananworanich et al., 2012, 2015; Eriksson et al., 2013), in which a
lower frequency of reservoir cells wasmeasured in subjectswho started
ART early when using Q-VOA, integrated HIV DNA in PBMCs and total
HIV DNA in resting CD4+ T cells.3.6. TILDA Reveals the Existence of a Large Pool of Latently Infected CD4+
T cells in HIV-infected Individuals who do not Receive ART
Our results conﬁrm that the latent HIV reservoir is established early
in infection (Strain et al., 2005; Archin et al., 2012; Buzon et al., 2014;
Ananworanich et al., 2012; Chomont et al., 2009). However, the relative
proportion of productively and latently infected CD4+ T cells during
untreated HIV infection is not known. As TILDA can measure the
frequency of cells spontaneously producing msRNA as well as the fre-
quency of cells that has the ability to do so upon maximal stimulation
(Fig. 1), we used our assay to measure both frequencies in CD4+
T cells obtained from HIV-infected individuals who did not receive
ART (Table 1). CD4+ T cells containing tat/rev transcripts at baseline
were readily detected in all samples from viremic individuals
(Fig. 4A). Overnight stimulation with PMA/ionomycin led to a signiﬁ-
cant increase in the frequency of CD4+ T cells producing msRNA
(median fold increase of 7.4 in the frequency of cells with HIV msRNA,
p = 0.0005). The frequency of cells spontaneously producing these
transcripts was strongly correlated with plasma viral load (r = 0.81,
p= 0.0014, Fig. 4B). Our calculations indicate that only aminor fraction
(18.6%) of CD4+ T cells with inducible HIV genomes were spontane-
ously producing tat/rev transcripts in vivo (Fig. 4C), whereas the major-
ity of infected cells (81.4%) were latently infected and producedmsRNA
only upon stimulation. Therefore, similar to virally suppressed subjects,
ART-naïve individuals harbour a large pool of CD4+ T cells in which
msRNA can be induced upon stimulation (Fig. 4D). The frequency of
latently infected CD4+ T cells in untreated HIV-infected individuals
was positively correlated with the duration of HIV infection (r = 0.71,
p = 0.0097, Fig. 4E), suggesting that the size of the latent and inducible
reservoir gradually increases in untreated viremic subjects, a conse-
quence of continuous seeding of the HIV reservoir.Fig. 4 TILDA reveals that untreated HIV-infected individuals harbour a large pool of latently infe
(baseline) or after 12 h of stimulation (induced) in 13 samples obtained from viremic, untreat
from the Wilcoxon matched-pairs signed rank test. (B) Correlation between the frequency of
obtained from the Pearson test. (C) Proportion of CD4+ T cells that produce tat/revmsRNA sp
the average relative proportions of productively and latently infected CD4+ T cells in virally su
from theMann–Whitney test. (E) Correlation between the frequency of CD4+T cells producing
Pearson test. (F) Frequency of CD4+T cells producingHIVmsRNA before and after stimulation
AZT). P values were obtained from theWilcoxon matched-pairs signed rank test.Non-integrated HIV DNA molecules are present at high frequencies
in CD4+ T cells isolated from viremic HIV-infected individuals
(Chomont et al., 2009; Koelsch et al., 2008). Integration and transcrip-
tion of these linear genomes may account for the increase in the
frequency of CD4+ T cells producingmsRNAwe observed upon stimu-
lation with PMA/ionomycin. To test for this possibility, we repeated
these experiments in the presence of antiretroviral drugs, including
the integrase inhibitor raltegravir. We observed that the addition of
raltegravir to the culture medium had no impact on the increase in
the frequency of cells producingmsRNA upon stimulation. This indicat-
ed that the increase in the frequency of CD4+ T cells producingmsRNA
is attributable to viral genomes that were already integrated before
stimulation, demonstrating that post-integration latency can be detect-
ed and measured in viremic HIV-infected subjects who do not receive
ART.4. Discussion
Thedeﬁnitive test of anHIV curewill require the interruption of ART.
It is necessary, however, tomeasure the impact of eradication strategies
on the size of the viral reservoir even as therapy is continued if clinical
trials are to proceed in an efﬁcient and ethical manner (International
ASSWGoHIVC et al., 2012). A large number of assays have been devel-
oped to measure the frequency of infected cells that persist in virally
suppressed subjects who have received ART for years (Lewin et al.,
1999; Li et al., 2010; Siliciano and Siliciano, 2005; Yu et al., 2008;
Palmer et al., 2003; Vandergeeten et al., 2014; Pasternak et al., 2008;
Eriksson et al., 2013; Brussel and Sonigo, 2003; Rouzioux et al., 2005;
Strain et al., 2013; O'Doherty et al., 2002). Each assaymeasures different
parameters (replication competent HIV, total and integrated HIV DNA,
cell associated HIV RNA, viral particles) in different cells types (PBMCs,
CD4+T cells and restingCD4+T cells). These assays provide a frequen-
cy of persistently infected cells that can range over 2 logs in the same in-
dividual (Eriksson et al., 2013). For example, the size of the reservoir is
likely to be overestimated by PCR assays, which can include a large pro-
portion of defective viruses. On the other hand, the reservoir is likely to
be underestimated by the Q-VOA assay as it does not capture all cells
carrying replication competent HIV (Ho et al., 2013). This prompted us
to develop an assay that would not measure the background attributed
to defective genomes and that would not rely on the ampliﬁcation of
viral replication, a step that requires at least seven days of cell culture.
Unlike cells that produce unspliced and often short HIV gag RNA
(Lassen et al., 2004), infected cells that are actively producing msRNA
(particularly tat/rev transcripts) can produce virions (Lewin et al.,
1999; Pasternak et al., 2008, 2009; Schmid et al., 2010; Fischer et al.,
2004; Peng et al., 1995; Hermankova et al., 2003; Vesanen et al.,
1997). This well-characterized process suggests that quantiﬁcation of
tat/rev msRNA may prove to be a sensitive and reproducible manner
to estimate the frequency of cells harbouring transcriptionally silent –
nonetheless inducible – viruses after maximal stimulation.
TILDA does not rely on the ampliﬁcation of viral replication and of-
fers similar advantages of the DNA PCR assays with regard to simplicity
and small blood volume requirement. It does not require RNA extraction
and 96-well plates with serially diluted cells can be stored at−80 °C for
future quantiﬁcation in batch analyses, making TILDA well-suited for
longitudinal clinical studies. Therefore, TILDA has a number of charac-
teristics that make it attractive for clinical trials, particularly incted CD4+ T cells. (A) Frequency of CD4+ T cells producing tat/revmsRNA spontaneously
ed HIV-infected individuals. Horizontal bars indicate median values. P value was obtained
CD4+ T cells spontaneously producing HIV msRNA and HIV plasma viremia. P value was
ontaneously or after stimulation in untreated HIV-infected subjects. (D) Pie charts show
ppressed (ART) and untreated viremic (VIR) HIV-infected subjects. P value was obtained
HIVmsRNA after stimulation and duration of HIV infection. P valuewas obtained from the
in the presence (+ARVs) or absence (−ARVs) of antiretrovirals (raltegravir, efavirenz and
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882 F.A. Procopio et al. / EBioMedicine 2 (2015) 874–883paediatric studies in which the number of cells that can be obtained are
often limited. In addition, TILDA could be used tomeasure the frequency
of infection in rare population of cells, whichmay facilitate themeasure-
ment of the HIV reservoir in tissues.
Using TILDA, we found the median frequency of latently infected
CD4+ T cells during ART to be 24 cells/million, which is 48 times
more than the frequency measured by the quantitative viral outgrowth
assay. Ho et al. recently reported that the median frequency of intact
noninduced proviruses is around 60-fold higher than the frequency of
induced proviruses detected in Q-VOA (Ho et al., 2013). Therefore,
TILDAmay provide an accurate estimate of the size of the latentHIV res-
ervoir, although the precise fraction of the replication competent latent
and inducible HIV reservoir captured by TILDAwill require further stud-
ies. Similarly, evaluating the ability of TILDA to predict viral rebound
upon ART interruption will necessitate the development of well-
powered clinical trials and cannot be inferred from our current
observations.
TILDA correlated with several PCR-based assays that measure the
size of the latent reservoir, including the quantiﬁcation of total and inte-
grated HIV DNA in PBMCs. TILDA tended to correlate with the size of the
reservoir measured by Q-VOA, but this was not statistically signiﬁcant.
Our data are consistent with a lack of strong correlation between
these two measures although the lack of statistical signiﬁcance may re-
ﬂect, in part, the sample size. The lack of correlation between the two
assaysmay also result from the fact that Q-VOA is performed onpuriﬁed
resting CD4+ T cells, whereas total CD4+ T cells are used for TILDA de-
terminations. Total CD4+ T cells include cells undergoing homeostatic
proliferation which express some activation markers and are not cap-
tured in the Q-VOA assay. Ho et al. reported that Q-VOA does not corre-
late strongly with the frequency of cells harbouring intact non-induced
proviruses (Ho et al., 2013), suggesting that it may not provide an accu-
rate estimate of the frequency of latently infected CD4+ T cells.Wheth-
er TILDA could provide a better estimate of the size of the replication
competent reservoir remains to be determined by using full-length se-
quencing approaches, similar to the ones used by Ho et al. and others
(Ho et al., 2013; Cohn et al., 2015).
Using TILDA, we observed that early initiation of ART leads to a re-
duced size of the viral reservoir after years of viral suppression. This is
in line with several reports that have clearly demonstrated the beneﬁt
of early therapy on the size of the latent HIV reservoir (Strain et al.,
2005; Archin et al., 2012; Buzon et al., 2014; Ananworanich et al.,
2012, 2015; Chomont et al., 2009). In addition, we demonstrated that
before the initiation of ART, the latent HIV reservoir already represents
a substantial fraction of all infected CD4+ T cells and that the size of
the reservoir increases with time during untreated HIV infection. This
observation further argues for early ART intervention to prevent the es-
tablishment and continuous seeding of an increasingly large pool of la-
tently infected CD4+ T cells.
Although TILDA constitutes an attractive alternative to other
methods tomeasure the size of the latentHIV reservoir, there are poten-
tial limitations associated with the use of our assay. First, although all
cells that are releasing viral particles are producing tat/revmsRNA, the
opposite may not be necessarily true. We cannot exclude the possibility
that some cells that generate a positive signal in TILDA do not produce
virions. Indeed, very low levels of nuclear msRNA can be detected in
resting CD4+ T cells using ultrasensitive approaches (Lassen et al.,
2004, 2006). Therefore, TILDA is likely to overestimate the size of the
latent and replication competent reservoir. Notwithstanding this limita-
tion, TILDA is more likely to capture the functional reservoir than other
existing PCR-based assays: TILDA positive events result from the tran-
scription of integrated HIV genomes that have an intact LTR (to ensure
transcription) and that are not deleted in the two most commonly de-
leted regions identiﬁed in defective genomes namely tat and rev (Ho
et al., 1995). Of note, TILDA measures frequencies of latently infected
CD4+ T cells close to those predicted to harbour replication competent
virus in the study by Ho et al. (2013). Another potential caveat of TILDAis the fact that it relies on the ampliﬁcation of a highly variable region of
the HIV genome, suggesting that the primers and probes used in our
assay may not recognize all viral quasispecies. We anticipate that the
use of TILDA on HIV clades other than B will require further validation
and optimization.
In conclusion, we report the development and validation of
TILDA, a novel assay to measure the size of the latent reservoir that
is quantitative, sensitive, robust and requires only 10 ml of blood.
Moreover, results can be generated in two days. As such, TILDA
may represent an alternative to existing assays used to evaluate the
efﬁcacy of therapeutic strategies aimed at reducing the size of the la-
tent HIV reservoir.
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.ebiom.2015.06.019.
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